For the Quarter Ending June 2026
Olmesartan Medoxomil Prices in APAC
- In China, the Olmesartan Medoxomil Price Index rose quarter-over-quarter in Q2 2026, driven by significant upward production cost pressures.
- In India, the Olmesartan Medoxomil Price Index stood at USD 135,000/MT during Q2 2026, supported by stable pharmaceutical procurement.
- Olmesartan Medoxomil production costs increased in Q2 2026, influenced by a 4.1% rise in producer prices year-over-year in June 2026.
- Petrochemical feedstock costs, including naphtha and olefins, surged during Q2 2026 due to Middle East conflict disruptions.
- Demand for Olmesartan Medoxomil was supported by a stable 5.0% unemployment rate in June 2026, ensuring patient access.
- China's pharmaceutical market demonstrated steady growth in 2026, driven by an aging population and chronic illnesses.
- Industrial production expanded by 5.3% year-over-year in June 2026, supporting Olmesartan Medoxomil supply capacity.
- The Manufacturing Index showed expanding activity in June 2026, indicating a healthy industrial environment.
- Overseas buyers held high inventories in May 2026, leading to reduced orders for Chinese chemicals.
- Normalization of Strait of Hormuz traffic in June 2026 intensified competition for Chinese chemical exports.
Why did the price of Olmesartan Medoxomil change in June 2026 in APAC?
- Rising input costs, evidenced by a 4.1% PPI year-over-year in June 2026, pressured Olmesartan Medoxomil prices upward.
- Surging petrochemical feedstock costs in Q2 2026, exacerbated by geopolitical tensions, increased production expenses.
- Steady pharmaceutical market growth in 2026, supported by stable employment, maintained demand.
Olmesartan Medoxomil Prices in North America
- In the United States, the Olmesartan Medoxomil Price Index rose quarter-over-quarter in Q2 2026, driven by elevated production costs and robust demand.
- Olmesartan Medoxomil production costs increased in Q2 2026, influenced by a 5.5% year-over-year Producer Price Index in June 2026.
- General chemical intermediate costs and industrial electricity prices strengthened in Q2 2026, impacting manufacturing expenses.
- Demand for Olmesartan Medoxomil was robust in Q2 2026, supported by a 6.9% year-over-year retail sales growth in May 2026.
- A low 4.2% unemployment rate in June 2026 enhanced patient access and affordability for Olmesartan Medoxomil.
- The US pharmaceutical market experienced sustained growth in Q2 2026, bolstering the Olmesartan Medoxomil demand outlook.
- Supply chains for chemicals faced disruptions in Q2 2026 due to geopolitical events, affecting overall availability.
- The Olmesartan Medoxomil Price Index faced upward pressure due to a 3.5% year-over-year Consumer Price Index in June 2026.
Why did the price of Olmesartan Medoxomil change in June 2026 in North America?
- Producer Price Index rose 5.5% year-over-year in June 2026, increasing Olmesartan Medoxomil manufacturing costs.
- Robust demand for antihypertensive drugs in North America persisted throughout Q2 2026, supporting market strength.
- General chemical intermediate costs and industrial electricity prices strengthened in Q2 2026, raising production expenses
Olmesartan Medoxomil Prices in Europe
- In Germany, the Olmesartan Medoxomil Price Index rose quarter-over-quarter in Q2 2026, driven by increased production costs.
- Producer prices for industrial products in Germany increased 2.2% year-on-year in May 2026, elevating Olmesartan Medoxomil costs.
- Mounting raw material costs and increased wholesale electricity prices in May 2026 pressured the German chemical industry.
- Germany's inflation rate, measured by CPI, was +2.3% in June 2026, indicating rising operational expenses.
- Demand for prescription drugs in Germany was bolstered by an aging society in 2026, supporting Olmesartan Medoxomil consumption.
- Germany's harmonised unemployment rate remained stable at 3.8% in May 2026, ensuring consistent demand.
- Supply chain disruptions intensified in the first half of 2026 due to the Strait of Hormuz closure, pushing up input prices.
- Germany's Manufacturing Index showed a contracting trend in June 2026, signaling a slowdown in industrial activity.
- The Olmesartan Medoxomil price forecast suggests continued upward pressure due to sustained input cost increases in Q2 2026.
Why did the price of Olmesartan Medoxomil change in June 2026 in Europe?
- Producer prices rose 2.2% in May 2026, increasing Olmesartan Medoxomil manufacturing expenses.
- Higher raw material costs and soaring power prices in May 2026 elevated Olmesartan Medoxomil production.
- Supply chain disruptions in Q2 2026, including the Strait of Hormuz closure, pushed up chemical input prices.
For the Quarter Ending March 2026
Olmesartan Medoxomil Prices in North America
- In United States, the Olmesartan Medoxomil Price Index rose quarter-over-quarter in Q1 2026, driven by escalating production costs.
- The Olmesartan Medoxomil Production Cost Trend increased in March 2026 as producer prices rose 4.0%.
- Consumer prices grew 3.3% year-over-year in March 2026, elevating transportation expenses for Olmesartan Medoxomil distribution.
- The Olmesartan Medoxomil Demand Outlook remained robust in March 2026, supported by 4.0% retail sales growth.
- A stable 4.3% unemployment rate in March 2026 sustained patient insurance access for Olmesartan Medoxomil prescriptions.
- The Manufacturing Index expanded in March 2026, ensuring steady industrial production for Olmesartan Medoxomil formulation.
- Upstream active pharmaceutical ingredient inventories for Olmesartan Medoxomil tightened in Q1 2026 amid overseas solvent shortages.
- Maritime freight disruptions delayed critical pharmaceutical and chemical imports into the United States in March 2026.
- The Olmesartan Medoxomil Price Forecast reflected upward pressure in Q1 2026 as crude oil benchmarks spiked.
Why did the price of Olmesartan Medoxomil change in March 2026 in North America?
- Toluene solvent costs surged in March 2026, directly increasing Olmesartan Medoxomil active pharmaceutical ingredient expenses.
- Maritime freight disruptions delayed chemical imports in March 2026, tightening domestic Olmesartan Medoxomil supply availability.
- Hospital patient admissions increased in Q1 2026, driving steady downstream demand for Olmesartan Medoxomil formulations.
Olmesartan Medoxomil Prices in APAC
- In China, the Olmesartan Medoxomil Price Index rose quarter-over-quarter in Q1 2026, driven by strengthened upstream naphtha costs.
- The Olmesartan Medoxomil Production Cost Trend increased in March 2026 as producer prices rose by 0.5 percent.
- A mild consumer price increase of 1.0 percent in March 2026 supported a stable Olmesartan Medoxomil Demand Outlook.
- Industrial production grew 5.7 percent in March 2026, ensuring steady manufacturing volumes for the Olmesartan Medoxomil Price Index.
- Retail sales grew 1.7 percent and unemployment reached 5.4 percent in March 2026, slightly pressuring domestic pharmaceutical markets.
- The Manufacturing Index expanded in March 2026, despite consumer confidence dropping to 91.6 during February 2026.
- Export demand for Chinese active pharmaceutical ingredients remained robust from the Indian market during March 2026.
- Chinese petrochemical plants reduced operating rates in January 2026, tightening regional supply of chemical feedstocks.
- Russian crude oil shipments surged in January 2026, securing upstream feedstocks for the Olmesartan Medoxomil Price Forecast.
Why did the price of Olmesartan Medoxomil change in March 2026 in APAC?
- Upstream naphtha costs strengthened in January 2026 due to fewer arriving arbitrage cargoes in Asia.
- Chinese petrochemical plants reduced operating rates in January 2026, tightening regional chemical feedstock supply availability.
- Export demand for active pharmaceutical ingredients remained robust from the Indian market in March 2026.
Olmesartan Medoxomil Prices in Europe
- In Germany, the Olmesartan Medoxomil Price Index rose quarter-over-quarter in Q1 2026, driven by surging feedstock costs.
- The Olmesartan Medoxomil Production Cost Trend increased in March 2026 as inflation reached 2.7 percent.
- Despite rising API costs, producer prices declined by -0.2 percent in March 2026 for basic reagents.
- Industrial production remained stagnant at 0.0 percent in February 2026, limiting domestic Olmesartan Medoxomil precursor availability.
- The Olmesartan Medoxomil Demand Outlook remained stable as retail sales grew 0.7 percent in February 2026.
- A low unemployment rate of 4.2 percent in February 2026 sustained prescription cardiovascular drug consumption.
- The Manufacturing Index expanded in March 2026, even though consumer confidence dropped to -24.7 index points.
- Toluene and benzene feedstock costs surged in March 2026, directly elevating the Olmesartan Medoxomil Price Forecast.
- Pharmaceutical manufacturing chemical feedstock availability tightened during March 2026 amid a severe European import supply crunch.
Why did the price of Olmesartan Medoxomil change in March 2026 in Europe?
- Geopolitical conflicts in the Middle East severely disrupted chemical supply chains throughout March 2026.
- European natural gas storage levels depleted significantly by March 2026, elevating energy-intensive synthesis expenses.
- A major regional petrochemical producer permanently halted operations at a key facility in Q1 2026.
For the Quarter Ending December 2025
Olmesartan Medoxomil Prices in APAC
- In China, the Olmesartan Medoxomil Price Index fell quarter-over-quarter in Q4 2025, due to declining basic chemical raw material producer prices.
- Olmesartan Medoxomil production costs declined in Q4 2025 as the producer price index fell by -1.9% in December 2025.
- Olmesartan Medoxomil demand was subdued in Q4 2025 with 0.9% retail sales growth and 5.1% unemployment in December 2025.
- Despite weak consumer inflation (CPI at 0.8% in December 2025), the manufacturing index expanded in December 2025.
- Industrial production increased by 5.2% in December 2025, indicating robust manufacturing activity and chemical input demand.
- Olmesartan Medoxomil price forecast suggests pressure from rising global overcapacity in chemical building blocks during 2025.
- China's exports remained resilient in Q4 2025, though new export orders declined in October and December 2025.
- The pharmaceutical industry experienced rapid growth in 2025, contrasting with decelerating overall economic growth in Q4 2025.
Why did the price of Olmesartan Medoxomil change in December 2025 in APAC?
- Producer prices for basic chemical raw materials declined by -1.9% in December 2025, reducing production costs.
- Domestic consumption remained subdued in December 2025, with retail sales growing only 0.9%, impacting demand.
- Weak consumer inflation, at 0.8% in December 2025, exerted downward pressure on pharmaceutical pricing.
Olmesartan Medoxomil Prices in North America
- In the United States, the Olmesartan Medoxomil Price Index rose quarter-over-quarter in Q4 2025, driven by increased production costs.
- Production costs for Olmesartan Medoxomil increased as CPI rose 2.7% year-over-year in December 2025, impacting raw materials.
- Input costs for pharmaceutical manufacturing climbed, with PPI increasing 3.0% year-over-year in November 2025.
- Demand for Olmesartan Medoxomil was supported by a 3.3% year-over-year rise in retail sales in November 2025.
- A strong labor market, with unemployment at 4.4% in December 2025, bolstered consumer purchasing power for medications.
- Industrial production expanded 2.0% year-over-year in December 2025, indicating a robust manufacturing base.
- The pharmaceutical market showed cautious optimism in Q4 2025, with sustained novel drug approvals through October 2025.
- Natural gas spot prices fluctuated in Q4 2025, softening in October but surging in early December.
Why did the price of Olmesartan Medoxomil change in December 2025 in North America?
- Rising input costs, with PPI increasing 3.0% year-over-year in November 2025, elevated manufacturing expenses.
- General inflation, CPI rising 2.7% year-over-year in December 2025, impacted raw material and operational costs.
- Strong consumer demand, supported by a 4.4% unemployment rate in December 2025, contributed to price stability.
Olmesartan Medoxomil Prices in Europe
- In Germany, the Olmesartan Medoxomil Price Index fell quarter-over-quarter in Q4 2025, driven by declining producer prices in December 2025.
- Olmesartan Medoxomil production costs decreased in December 2025, as producer prices declined by 2.5% year-on-year.
- The demand outlook for Olmesartan Medoxomil remained subdued in Q4 2025, reflecting contracting manufacturing activity in December 2025.
- Consumer activity in Germany was relatively subdued in Q4 2025, impacting overall healthcare spending capacity.
- Energy costs in Germany continued to ease inflation in November 2025, contributing to lower operational expenses.
- Germany's industrial production grew by 0.8% year-on-year in October 2025, supporting consistent supply chain operations.
- The Manufacturing Index trend was contracting in December 2025, indicating a slowdown in broader economic activity.
- Moderate CPI of 1.8%, 6.2% unemployment, and low consumer confidence in December 2025 impacted patient affordability.
Why did the price of Olmesartan Medoxomil change in December 2025 in Europe?
- Producer prices in Germany declined by 2.5% year-on-year in December 2025, reducing manufacturing input costs.
- Consumer confidence was significantly pessimistic at -17.5 in December 2025, impacting patient spending on healthcare.
- The Manufacturing Index contracted in December 2025, signaling a broader economic slowdown affecting market sentiment.
For the Quarter Ending September 2025
Olmesartan Medoxomil Prices in North America
- In the United States, Olmesartan Medoxomil Price Index rose in Q3 2025, reflecting higher production costs.
- Production costs rose, with PPI up 2.6% in August and CPI 3.0% in September 2025.
- Demand supported by robust retail sales, climbing 5.42% year-over-year in September 2025.
- Low unemployment at 4.3% in September 2025 bolstered healthcare access, impacting demand.
- Chemical inventories tightened in Q3 2025 due to accelerated destocking and declining finished goods.
- U.S. natural gas prices experienced an uptick in Q3 2025, adding to energy feedstock costs.
- Pharmaceutical sector activity surged in Q3 2025, driven by regulatory developments and business deals.
- Consumer confidence declined to 94.2 in September 2025, leading to more cautious healthcare spending.
- Industrial production growth was sluggish at 0.1% in September 2025, reflecting weak overall activity.
Why did the price of Olmesartan Medoxomil change in September 2025 in North America?
- Rising input costs, with PPI up 2.6% in August 2025, pressured Olmesartan Medoxomil production.
- Tightening chemical inventories and declining U.S. production levels constrained supply in Q3 2025.
- Robust retail sales, up 5.42% in September 2025, supported demand despite cost increases.
Olmesartan Medoxomil Prices in APAC
- In China, the Olmesartan Medoxomil Price Index fell quarter-over-quarter in Q3 2025, influenced by declining producer prices and weakening feedstock costs.
- Olmesartan Medoxomil production costs declined in Q3 2025, as producer prices fell 2.3% year-on-year in September 2025.
- Demand for Olmesartan Medoxomil remained robust in Q3 2025, supported by China's aging population and pharmaceutical market growth.
- Industrial production rose 6.5% year-on-year in September 2025, yet the Manufacturing Index contracted.
- Consumer confidence at 89.6 and negative CPI of -0.3% year-on-year in September indicated deflationary conditions.
- Feedstock costs for chemical building blocks weakened in Q3 2025, pressuring Olmesartan Medoxomil expenses downward.
- The Olmesartan Medoxomil Price Forecast suggests continued pressure from global chemical overcapacity and declining energy.
- China's pharmaceutical and API exports strengthened in Q3 2025, reflecting healthy international trade flows.
Why did the price of Olmesartan Medoxomil change in September 2025 in APAC?
- Producer prices declined 2.3% year-on-year in September 2025, reducing Olmesartan Medoxomil production costs.
- Feedstock costs for chemical building blocks weakened in Q3 2025, alongside declining natural gas.
- Contracting Manufacturing Index and negative CPI in September 2025 exerted downward pricing pressure.
Olmesartan Medoxomil Prices in Europe
- In Germany, the Olmesartan Medoxomil Price Index rose quarter-over-quarter in Q3 2025, driven by robust demand and tightening supply.
- Olmesartan Medoxomil price is positioned for continued upward movement given sustained demand and supply constraints.
- Production costs faced upward pressure from elevated general chemical input costs and increased wholesale electricity prices in Q3 2025.
- Demand for cardiovascular drugs, including Olmesartan Medoxomil, remained robust in Germany throughout Q3 2025.
- Overall German chemical production contracted in Q3 2025, with industrial production declining -1.0% year-over-year in September 2025.
- The Manufacturing Index trended Contracting in September 2025, reflecting a slowdown in overall industrial activity.
- A low unemployment rate of 3.9% in September 2025 supported demand, while retail sales grew 0.8% year-over-year.
- Producer prices declined -1.7% year-over-year in September 2025, moderating input costs despite CPI increasing 2.4%.
- Negative consumer confidence at -23.6 in September 2025 indirectly pressured healthcare spending and market stability.
Why did the price of Olmesartan Medoxomil change in September 2025 in Europe?
- Robust cardiovascular drug demand, driven by aging population and market expansion.
- Contracting German chemical production and facility shutdowns tightened supply.
- Elevated chemical input costs and increased electricity prices pressured production.
